135 related articles for article (PubMed ID: 36894908)
1. Performance of Aptima-HPV in the cervical cancer screening program of Portugal: a cost-analysis.
Figueiredo D; Ribeiro I; Penedones A; Mendes D; Alves C; Batel-Marques F; da Silva DP
BMC Womens Health; 2023 Mar; 23(1):96. PubMed ID: 36894908
[TBL] [Abstract][Full Text] [Related]
2. HPV Prevalence in the Dutch cervical cancer screening population (DuSC study): HPV testing using automated HC2, cobas and Aptima workflows.
Huijsmans CJ; Geurts-Giele WR; Leeijen C; Hazenberg HL; van Beek J; de Wild C; van der Linden JC; van den Brule AJ
BMC Cancer; 2016 Nov; 16(1):922. PubMed ID: 27894291
[TBL] [Abstract][Full Text] [Related]
3. Cross-reactivity profiles of hybrid capture II, cobas, and APTIMA human papillomavirus assays: split-sample study.
Preisler S; Rebolj M; Ejegod DM; Lynge E; Rygaard C; Bonde J
BMC Cancer; 2016 Jul; 16():510. PubMed ID: 27439470
[TBL] [Abstract][Full Text] [Related]
4. Use of the Aptima mRNA high-risk human papillomavirus (HR-HPV) assay compared to a DNA HR-HPV assay in the English cervical screening programme: a decision tree model based economic evaluation.
Weston G; Dombrowski C; Harvey MJ; Iftner T; Kyrgiou M; Founta C; Adams EJ
BMJ Open; 2020 Mar; 10(3):e031303. PubMed ID: 32152154
[TBL] [Abstract][Full Text] [Related]
5. HPV genotyping and E6/E7 transcript assays for cervical lesion detection in an Asian screening population-Cobas and Aptima HPV tests.
Wong OGW; Tsun OKL; Tsui EY; Chow JNK; Ip PPC; Cheung ANY
J Clin Virol; 2018 Dec; 109():13-18. PubMed ID: 30368218
[TBL] [Abstract][Full Text] [Related]
6. The APTIMA HPV assay versus the Hybrid Capture 2 test in triage of women with ASC-US or LSIL cervical cytology: a meta-analysis of the diagnostic accuracy.
Arbyn M; Roelens J; Cuschieri K; Cuzick J; Szarewski A; Ratnam S; Reuschenbach M; Belinson S; Belinson JL; Monsonego J
Int J Cancer; 2013 Jan; 132(1):101-8. PubMed ID: 22610699
[TBL] [Abstract][Full Text] [Related]
7. Human Papillomavirus Assays and Cytology in Primary Cervical Screening of Women Aged 30 Years and Above.
Rebolj M; Bonde J; Preisler S; Ejegod D; Rygaard C; Lynge E
PLoS One; 2016; 11(1):e0147326. PubMed ID: 26789267
[TBL] [Abstract][Full Text] [Related]
8. Budget impact analysis of cervical cancer screening in Portugal: comparison of cytology and primary HPV screening strategies.
Pista A; Costa C; Saldanha C; Moutinho JAF; Moutinho JM; Arrobas F; Catalão C; Kempers J
BMC Public Health; 2019 Feb; 19(1):235. PubMed ID: 30808324
[TBL] [Abstract][Full Text] [Related]
9. Comparison of Aptima and hybrid capture-2 HPV tests and Pap test in the referral population in Japan.
Kuroki H; Sakamoto J; Shibata T; Takakura M; Sasagawa T
J Med Virol; 2021 Aug; 93(8):5076-5083. PubMed ID: 33634473
[TBL] [Abstract][Full Text] [Related]
10. Comparative cost analysis of cervical cancer screening programme based on molecular detection of HPV in Spain.
Ibáñez R; Mareque M; Granados R; Andía D; García-Rojo M; Quílez JC; Oyagüez I
BMC Womens Health; 2021 Apr; 21(1):178. PubMed ID: 33902553
[TBL] [Abstract][Full Text] [Related]
11. Immediate histopathologic follow-up of cervista and aptima high-risk HPV assays in women with LSIL cytology.
Zhang H; Varma KR; Han M; Matsko J; Zhao C
Cancer Cytopathol; 2018 Aug; 126(8):525-532. PubMed ID: 29797678
[TBL] [Abstract][Full Text] [Related]
12. Performance of Aptima and Cobas HPV testing platforms in detecting high-grade cervical dysplasia and cancer.
Ge Y; Christensen P; Luna E; Armylagos D; Schwartz MR; Mody DR
Cancer Cytopathol; 2017 Aug; 125(8):652-657. PubMed ID: 28574670
[TBL] [Abstract][Full Text] [Related]
13. Aptima HPV Assay versus Hybrid Capture
Cook DA; Smith LW; Law J; Mei W; van Niekerk DJ; Ceballos K; Gondara L; Franco EL; Coldman AJ; Ogilvie GS; Jang D; Chernesky M; Krajden M
J Clin Virol; 2017 Feb; 87():23-29. PubMed ID: 27988420
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the Aptima and Cervista tests for detection of high-risk human papillomavirus in cervical cytology specimens.
Nolte FS; Ribeiro-Nesbitt DG
Am J Clin Pathol; 2014 Oct; 142(4):561-6. PubMed ID: 25239425
[TBL] [Abstract][Full Text] [Related]
15. [HPV E6 and E7 mRNA combined with HPV 16 and 18 or 45 genotyping testing as a means of cervical cancer opportunistic screening].
Wang JJ; Dong J; Deng ZX; Wang PF; Zhang XX; Du Y
Zhonghua Fu Chan Ke Za Zhi; 2019 May; 54(5):301-306. PubMed ID: 31154710
[No Abstract] [Full Text] [Related]
16. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
[TBL] [Abstract][Full Text] [Related]
17. [Evaluation of the effectiveness of BMRT-HPV for cervical cancer screening].
Duan LF; Du H; Wang C; Huang X; Qu XF; Duan XZ; Liu Y; Shi B; Zhang W; Wei LH; Belinson L; Wu RF
Zhonghua Fu Chan Ke Za Zhi; 2020 Oct; 55(10):708-715. PubMed ID: 33120484
[No Abstract] [Full Text] [Related]
18. Primary cervical cancer screening and triage using an mRNA human papillomavirus assay and visual inspection.
Nieves L; Enerson CL; Belinson S; Brainard J; Chiesa-Vottero A; Nagore N; Booth C; Pérez AG; Chávez-Avilés MN; Belinson J
Int J Gynecol Cancer; 2013 Mar; 23(3):513-8. PubMed ID: 23334437
[TBL] [Abstract][Full Text] [Related]
19. Accuracy and effectiveness of HPV mRNA testing in cervical cancer screening: a systematic review and meta-analysis.
Arbyn M; Simon M; de Sanjosé S; Clarke MA; Poljak M; Rezhake R; Berkhof J; Nyaga V; Gultekin M; Canfell K; Wentzensen N
Lancet Oncol; 2022 Jul; 23(7):950-960. PubMed ID: 35709810
[TBL] [Abstract][Full Text] [Related]
20. HPV Genotyping from the high risk mRNA Aptima assay- a direct approach using DNA from Aptima sample tubes.
Lillsunde Larsson G; Kaliff M; Bergengren L; Karlsson MG; Helenius G
J Virol Methods; 2016 Sep; 235():80-84. PubMed ID: 27233487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
